Program
Folfox protocol
Also written as “sunitinib + FOLFOX”, “FOLFOX” and “FOLFOX regimen”.
Its studies are mostly in Colorectal Neoplasms · Cholangiocarcinoma · Stomach Neoplasms · Neoplasms, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 31 open or running | phase 1since Feb 23, 2009 | Feb 23, 2009 | Aug 31, 2030phase 1 · NCT04929223 |
| AstraZeneca | 21 open or running | phase 3since Nov 13, 2006 | Nov 13, 2006 | Nov 30, 2027phase 2 · NCT05702229 |
| Pfizer | 20 open or running | phase 2since Feb 1, 2008 | Jan 11, 2008 | none ahead |
| Alethia Biotherapeutics | 11 open or running | phase 2since Nov 17, 2023 | Nov 17, 2023 | none ahead |
| Amgen | 10 open or running | phase 2since Mar 20, 2009 | Mar 20, 2009 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 1since May 24, 2007 | May 24, 2007 | none ahead |
| Cardiff Oncology | 11 open or running | phase 2since Oct 24, 2023 | Oct 24, 2023 | Apr 16, 2027phase 2 · NCT06106308 |
| Fosun Pharma | 11 open or running | phase 2since Apr 2, 2025 | Apr 2, 2025 | Apr 30, 2028phase 2 · NCT06936527 |
| Genmab | 11 open or running | phase 2since Apr 4, 2018 | Apr 4, 2018 | May 2028phase 2 · NCT03526835 |
| Lisata Therapeutics | 10 open or running | phase 2since Jan 26, 2023 | Jan 26, 2023 | none ahead |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 2since Oct 22, 2008 | Oct 22, 2008 | none ahead |
Also a collaborator on its studies: merck-pte-ltd-singapore.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Nov 13, 2006.
- May 24, 2007Bristol-Myers Squibb's first study: phase 1 study in NeoplasmsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00479583 · 25 enrolled · United States, France
- Jan 11, 2008Pfizer's first study: phase 1 study in Colorectal NeoplasmsNew to PfizerPfizer · NCT00599924 · 53 enrolled · United States
- Feb 1, 2008Phase 2 study in Colorectal NeoplasmsPfizer · NCT00615056 · 171 enrolled · United States, Canada, France and more
- Oct 22, 2008Merck KGaA, Darmstadt, Germany's first study: phase 2 study in Colorectal NeoplasmsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT00778830 · 289 enrolled · Singapore
- Feb 23, 2009Hoffmann-La Roche's first study: phase 1 study in Colorectal NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT00851136 · 9 enrolled
- Mar 5, 2009Phase 1 study in Colorectal NeoplasmsHoffmann-La Roche · NCT00873756 · 23 enrolled · United States
- Mar 20, 2009Amgen's first study: phase 2 study in Colorectal NeoplasmsNew to AmgenAmgen · NCT00866944 · 35 enrolled · France, Germany
- Apr 4, 2018Genmab's first study: phase 2 study in Colorectal NeoplasmsNew to GenmabGenmab · NCT03526835 · 560 planned · United States, Belgium, France and more
- Jun 11, 2021Phase 1 study in Colorectal NeoplasmsHoffmann-La Roche · NCT04929223 · 542 planned · United States, Australia, Canada and more
- Dec 7, 2022Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229 · 163 planned · United States, China, Japan and more
- Jan 26, 2023Lisata Therapeutics's first study: phase 2 study in CholangiocarcinomaNew to Lisata TherapeuticsLisata Therapeutics · NCT05712356 · 66 enrolled · United States
- Oct 24, 2023Cardiff Oncology's first study: phase 2 study in Colorectal NeoplasmsNew to Cardiff OncologyCardiff Oncology · NCT06106308 · 110 enrolled · United States
- Nov 17, 2023Alethia Biotherapeutics's first study: phase 2 study in Colorectal NeoplasmsNew to Alethia BiotherapeuticsAlethia Biotherapeutics · NCT06225843 · 17 planned · Canada
- Apr 2, 2025Fosun Pharma's first study: phase 2 study in Colorectal NeoplasmsNew to Fosun PharmaFosun Pharma · NCT06936527 · 102 planned · China
Ahead
- Apr 16, 2027Primary completion: phase 2 study in Colorectal NeoplasmsCardiff Oncology · NCT06106308
- Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229
- Apr 30, 2028Primary completion: phase 2 study in Colorectal NeoplasmsFosun Pharma · NCT06936527
- May 2028Primary completion: phase 2 study in Colorectal NeoplasmsGenmab · NCT03526835
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06936527Colorectal Neoplasms · China | 2 | By invitation | Fosun Pharma | Apr 30, 2028 | 102 |
| NCT06225843Colorectal Neoplasms · Canada | 2 | Recruiting | Alethia Biotherapeutics | Mar 2026 | 17 |
| NCT06106308Colorectal Neoplasms · United States | 2 | Active, not recruiting | Cardiff Oncology | Apr 16, 2027 | 110 |
| NCT05712356Cholangiocarcinoma · United States | 2 | Completed | Lisata Therapeutics | Apr 5, 2026 | 66 |
| NCT05702229Stomach Neoplasms · United States, China, Japan and more | 2 | Recruiting | AstraZeneca | Nov 30, 2027 | 163 |
| NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more | 1 | Recruiting | Hoffmann-La Roche | Aug 31, 2030 | 542 |
| NCT03526835Colorectal Neoplasms · United States, Belgium, France and more | 2 | Recruiting | Genmab | May 2028 | 560 |
| NCT00866944Colorectal Neoplasms · France, Germany | 2 | Completed | Amgen | Jul 2011 | 35 |
| NCT00873756Colorectal Neoplasms · United States | 1 | Completed | Hoffmann-La Roche | Mar 2014 | 23 |
| NCT00851136Colorectal Neoplasms | 1 | Completed | Hoffmann-La Roche | Jun 2010 | 9 |
| NCT00778830Colorectal Neoplasms · Singapore | 2 | Completed | Merck KGaA, Darmstadt, Germany | Apr 2014 | 289 |
| NCT00615056Colorectal Neoplasms · United States, Canada, France and more | 2 | Completed | Pfizer | Mar 2011 | 171 |
| NCT00599924Colorectal Neoplasms · United States | 1 | Completed | Pfizer | Nov 2008 | 53 |
| NCT00479583Neoplasms · United States, France | 1 | Completed | Bristol-Myers Squibb | Apr 2010 | 25 |
| NCT00399035Colorectal Neoplasms · Argentina, Australia, Brazil and more | 3 | Completed | AstraZeneca | Mar 2010 | 1,254 |
How it is read
Names in the registry
- “sunitinib + FOLFOX”, 7 entries
- “FOLFOX”, 6 entries
- “FOLFOX regimen”, 2 entries
- “FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])”, 2 entries
- “MCLA-158 + FOLFOX”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 12 studies
- Cholangiocarcinoma, 1 study
- Stomach Neoplasms, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.